Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-04-15

FDA Approved: JENTADUETO — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved a supplemental NDA for JENTADUETO (linagliptin and metformin hydrochloride) from Boehringer Ingelheim Pharmaceuticals, Inc. to update the label…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Jentadueto (linagliptin/metformin)

Snippet

SUPPL AP for JENTADUETO (LINAGLIPTIN AND METFORMIN HYDROCHLORIDE)